

An Overview on Allergen Immunotherapy for Allergic Asthma with Emphasis on Subcutaneous and Sublingual Immunotherapy

Arun Prakash Pullanikkad¹, Navami Nambiar², Aswani udayababu³, Abina Giri P⁴, Rinku Martin⁵, Aswathy K N⁶, Vidya Viswanad⁷

Amrita School of Pharmacy/Department of Pharmaceutics/ Amrita Vishwa Vidyapeetham/ AIMS Health Sciences
Campus/ Kochi- 682 041/ Kerala/ India

Corresponding author email id: vidyaviswanad@aims.amrita.edu

ABSTRACT

Allergen immunotherapy [AIT] has been diagnosed as a brand-new form of treatment for allergic asthma resulting from the massive launch of immune mediators. AIT is especially used to increase the prevalence, and when the usual drug remedy can't manipulate allergic allergies, it induces immune tolerance and changes the course of the sickness by continuing to alleviate signs. Subcutaneous immunotherapy [SCIT] changed into the pioneer method that were practiced for an extended time while Sublingual immunotherapy [SLIT] additionally indicates a few essential clinical documentations displaying an affected person-pleasant conception for immunotherapy. AIT represents an investment if you want to come sustained edges from progressed diagnosis and a mitigated burden of disease. The important thing mechanism for remedy is by exposing an affected person to an applicable substance [allergen] that finally ends up in tolerance to a selected allergen. The subcutaneous route is the traditional way of immunotherapy through increasing the dose to the most tolerable degree, even as the sublingual course is specifically drops [liquid] or pills, and has also shown obvious results. Thus, the article suggests the cutting-edge clinical suggestions are especially targeted on patient education, warding off allergens, pharmacotherapy and immunotherapy as the only way to suppress allergic asthma.

Keywords:

Allergen immunotherapy, Hypersensitivity, Subcutaneous immunotherapy, Sublingual immunotherapy, bronchial smooth muscles.

Introduction

Allergic asthma is due to the sensitization of a particular allergen that leads to the immune reaction by means of the discharge of immune mediators. This chronic infection is associated with airway hyperresponsiveness as a result of a particular allergen, viruses and some physical workouts leads to the frightful symptoms of asthma.[1] Unfavourably susceptible Asthma has identified with T helper cells type-2 (Th2) insusceptible reactions, which may be standard of various atopic conditions. Asthma triggers may likewise cause by (e.g., home earth vermin, cockroach build-up, creature dander, form, and dusts) and non-hypersensitive (e.g., viral diseases, tobacco smoke, bloodless air, work out) improvements, which produce a course of events fundamental to consistent aviation route irritation.[2]

Allergic reactions expand while someone's immune gadget overreacts to materials which are typically harmless. The first time someone is uncovered to an allergen, they do no longer typically reveal in a reaction. It regularly takes time for the immune gadget to accumulate a sensitivity to the substance. In time, the immune gadget learns to apprehend and consider the allergen. As it does so, it begins off evolved making antibodies to assault it while publicity occurs. This buildup is called sensitization that leads to allergic asthma or extrinsic asthma (hyperimmune response by inhalation of specific allergen).[3]

Allergens are of two sorts; the principal kind envelops any non-irresistible natural substance that may set off IgE creation to instigate an unfavourably susceptible response. Normal reasserts of allergens comprise of grass and tree dust, creature dander, house-dust-bug faecal particles, positive food varieties (peanuts, fish, milk, and eggs), a couple of medication medicines, and bug toxins. In a couple of cases, allergen-specific IgE coordinated towards abroad antigens additionally can comprehend cross-receptive host antigens, anyway the logical significance of that is indistinct. The

subsequent kind is a non-irresistible ecological substance that may set off a versatile invulnerable response identified with neighbourhood contamination anyway is thought to emerge autonomously of IgE. [4]

At one extreme, anaphylaxis and asthma may be existence-threatening arise deaths frequently in younger human beings that are avoidable. Fortunately, maximum allergic disorders aren't existence-threatening, however they all purpose misery and distress for millions — frequently at a time of their lives after they should be maximum active. Allergic rhinitis, bronchial allergies and eczema all intervene with sleep, intellectual functioning and leisure activities, while taking food hypersensitive reaction results in considerable anxieties for worry of inadvertently ingesting the offending allergen. This can be overcome using either sublingual or subcutaneous immunotherapy technique.[5]

Pathogenesis of allergic asthma

The airway inflammation is caused by the trigger of allergens that results in the discharge of immunomodulators inflicting unessential asthma attack, repeated inflammation is caused by remodelling of the airway walls by the formation of inflammatory mediators. Airway is limited by sleek muscle constriction (membrane puffiness and mucus accumulation).[6]The common term that explains allergic asthma is characterized by increased tracheobronchial responsiveness to a variety of stimuli (allergens). Allergen, kind of infection happens at bronchial smooth muscles. Cells engaged with aggravation are macrophages, mast cells, dendritic cells, eosinophils, neutrophils, and T lymphocytes that have interceded through granule discharge that prompts the arrival of safe middle people causing type 1 extremely hypersensitive response. [7]




Figure 1. Pathogenesis of allergic asthma

Standardization of allergen

Allergens, small enough to be breathed deep into the lungs, include: Windblown pollen from trees, grasses, and weeds, mold spores and fragments, animal dander (from hair, skin, or feathers) and saliva, dust mite faeces, Cockroach faeces. Allergens are not completely responsible for this triggered condition, in most of the cases certain irritants may also cause asthma.

Regardless of whether you have hypersensitive asthma or non-unfavorably susceptible asthma, the side effects are for the most part the equivalent. You're probably going to have symptoms such as rapid inhalation, shortness of breath, coughing, and wheezing, chest tightened the quality of the allergen vaccine is very important in testing and treatment.[8]

Where possible, standardized principles of known energy and shelf life should be used. The most common vaccines used in the treatment of allergic reactions are also now available as standard products or waiting to be standardized. Immunotherapy works by altering T-cells responses with viral mutations (increased T-helper cell 0 /T helper cell 1), T cell energy (decreased T helper cell 2/ T-helper cell 0) or, possibly, both. (9)

Significant imbalance of Th1 /Th2 and Th17/Treg has been linked to the pathogenesis of asthma. Type 2 immunity is the most common type of asthma immune response. Th17 and Treg cell immune response also play a significant role. ILC2 is an innate immune cell that plays vital role in the onset and asthma due to allergy. (10)

Patients during this sample were people who met the subsequent criteria: were diagnosed with hypersensitivity reaction asthma attach in keeping with GINA guidelines; had a positive skin prick check for Dp; and body fluid Dp specific immune serum globulin levels category 2; and had allergic symptoms that might be attributed to mites. All 3 necessities were met by all of the patients. Skin tests for nineteen different kinds of inhalant allergens were conducted. Histamine (10mg/ml) and dilutant were employed in this experiment.

All of the patients got Alu- tard Dp vaccinium as a part of a standardized SCIT. Weekly injections got throughout the initial section of SCIT to attain associate degree applicable dose. Patients had to endure a physical examination, a peak breath flow (PEF) take a look at (only patients with a PEF of >80% of the mean were allowed to receive the injection), and a dose adjustment assessment of native and SRs once a previous injection. (11)

Allergen immunotherapy

Allergen immunotherapy plays a significant role in modifying and transforming the exact route of hypersensitivity leading to asthma. This is one of the major important inventions made till date so as to increase the candidate's forbearance against specific type of allergens. Both of them seem to be of up to twelve years' effective length and can aid in averting conditions like allergen induced asthma and also certain cases of allergic rhinitis, they also play a major role in fending off certain new susceptibility towards asthma. [12]

Allergen immunotherapy (AIT) is the only kind of respiratory allergy medication that has the ability to alter the disease's path. The main mechanism working behind this is the induction of allergen specific immune tolerance. Thus, in adequately chosen patients with allergic asthma AIT is a possible therapeutic choice. [13]

Subcutaneous immunotherapy (SCIT)

Subcutaneous immunotherapy is a concept used to define a method of administering regular doses of a single allergen to combat IgE-mediated allergic disease. The standard SCIT protocol, which uses unaltered extracts of certain allergens usually, entails dose accumulation when given by SC route, which is further accompanied by maintenance doses given 5 or 7 weeks. Through the use of altered allergic extracts there was very less dose accumulation observed which was found to be feasible.

Subcutaneous immunotherapy started when in 1911 Dr. L. Noon and Dr. J Freeman published their results about desensitization of allergies by subcutaneous pollen extract injections. [14]

SCIT was found to be quite inefficacious at small amount and can lead to unacceptable systemic reaction at high doses. Isopathy is a homoeopathic approach that involves the use of causal agent or constituents of the same disease. A study was performed to check the effectiveness of this isopathic immunotherapy given via SC route along with HD OVA which is a term indicated as high diluted ovalbumin which was used in treatment of allergic asthma. A species of albino rat was treated with ovalbumin induced allergic asthma.

It was found that SCIT used in isopathic form was found to dramatically decrease the infections in pleura; also, the eosinophil count was found to be reduced in the Broncho alveolar fluid, also IL4 and IGE development decreased. The generation of Transforming Growth Factor beta and certain population of T cells is also increased. Such results show that the treatment of allergic asthma may be an appropriate candidate for under cutaneous isopathic immunotherapy. [15]

The use of long-term maintenance drugs is reduced with subcutaneous immunotherapy. It can also increase quality of life and FEV1 (a measure of exhalation capacity), as well as decrease the use of short-acting bronchodilators and systemic corticosteroids. Local and systemic responses to subcutaneous and sublingual immunotherapy are normal but seldom necessitate medication adjustments. Rarely, life-threatening incidents (such as anaphylaxis) are recorded. [16]

Omalizumab has been used to treat co-morbid asthma conditions in conjunction with inhalant allergen immunotherapy. Although no randomized clinical trials have been conducted to evaluate the addition of omalizumab to venom IT, numerous case reports and limited patient series on the use of omalizumab with venom IT have been reported. Omalizumab has been used in multi-allergen protocols in combination with oral immunotherapy to combat milk, peanut, and egg allergies, as well as other items. Finally, omalizumab used in combination with immunotherapy has shown promising effects, especially in terms of reducing adverse reactions. Larger, randomized, placebo-controlled studies are required at this point to help determine the patients will benefit the most from the addition of omalizumab to immunotherapy, as well as optimum dosing protocols and treatment length. [17] Subcutaneous immunotherapy (SCIT) has a number of drawbacks, including the risk of anaphylactic reactions, which led researchers to look for safer ways to administer allergen extracts. [18]

Sublingual immunotherapy (SLIT)

The fundamental theme in allergen immunotherapy is the possibility to change the normal history of hypersensitivity by forestalling the production of new refinements or the deteriorating of the condition, just as working even after the treatment is halted; the last viewpoint is connected to immunotherapy systems of activity. [19] Another significant factor to consider is cost-effectiveness. There are two stages of allergy shot therapy – In the first step, increasing quantities of allergen

extract are injected frequently. After that, a maintenance period occurs, during which injections are provided about once a month.[20]

Sublingual immunotherapy (SLIT) sensitivity tablets are another type of hypersensitivity immunotherapy that was as of late supported all through the United States.[21] Rather than injections, allergy tablets require sublingual administration of allergens in the form of a liquid or tablet on a regular basis [22]. Sublingual immunotherapy (SLIT) is an alternative to injections for treating allergies. In terms of controlling allergy symptoms, SLIT (allergy tablets) is similar to SCIT, and both have been shown to offer long-term relief even after treatment has ended [23]. Under the tongue tablets increase exposure to the drug you're allergic to while still reducing symptoms.

Four sensitivity tablet drugs have been endorsed by the US Food and Drug Administration (FDA). Two of them are for different sorts of grass dust, one for dust vermin, and one for short ragweed. Oralair® (Stallergenes-Greer), which contains five sorts of northern grass dust, and Grastek® (ALK Inc.), which contains timothy grass pollen, are the two grass pollen allergy pills. Ragwitek® is the brand name for a short ragweed allergy tablet (ALK Inc.). Odactra® is the brand name of the dust mite tablet (ALK Inc.). These four allergy tablets add to the treatment options for allergic rhinitis/rhino conjunctivitis caused by dust mites, ragweed, or timothy/northern grasses. The aim of SLIT is to reduce the body's allergic reaction, which triggers asthma symptoms, by administering under the tongue repeated doses of the allergen in liquid or tablet form.[24]

The moderating effect of immunotherapy, including Cut, is dependent upon the ability to change the total of White blood cells, which is portrayed by a power of the Th2 structure in touchy subjects, with the improvement of IL-4, IL-5, IL-13, IL-17, and IL-32 cytokines. [25]

Sublingual immunotherapy (SLIT) has fulfilled this need with clinical efficacy equivalent to SCIT. In reality, a comprehensive review of the available literature revealed that the safety profile was largely free of severe systemic reactions.[26]

In the early stages of SLIT, the medication costs are added to the expense of symptomatic medications, but when therapeutic effectiveness improves, drug intake decreases. Studies have shown that SLIT is helpful in the treatment of unfavorably susceptible rhinitis, diminishing clinical indications, and the utilization of against hypersensitive drugs. SLIT can only be used by people who have asthma that is difficult to manage with conventional therapies, according to most asthma care recommendations. Severe unnecessary side effects were no more or less likely in those who received SLIT, but they were usually mild and infrequent. In the same way that SCIT prevented the improvement of new refinements and the event of asthma in rhinitis patients, SLIT exhibited the capacity to forestall the advancement of new refinements and the beginning of asthma in rhinitis patients are dirtied air, fragrances, room revitalizers, solid synthetic exhaust and so on.[27]

Challenges faced in subcutaneous and sublingual immunotherapy

Subcutaneous and sublingual allergy immunotherapy or inhalant allergens have been shown to be effective in treating allergic rhinitis and allergic asthma, with minimal evidence for effectiveness in selected patients with atopic dermatitis. Many random double-blind trials of certain standardized extracts have been performed hence determining the doses which may be effective or less effective. There was no noteworthy contrast appearing between SCIT and SLIT based on the improvement of the symptoms and use of rescue medication. [28]

SUBCUTANEOUS IMMUNOTHERAPY	SUBLINGUAL IMMUNOTHERAPY
<ul style="list-style-type: none"> • They are injected into the upper arm • They can be easily monitored while the treatment process is going on • Side effects such as pain and swelling occur at the site of action • They may improve the symptoms of asthma in a constructive asthma • The dose can only be given in the hospital • They have risk of anaphylactic shock • They have a hefty of injection procedures 	<ul style="list-style-type: none"> • They are given in the form of liquid or tablet under the tongue • The monitoring process may be complex • Side effects are usually swelling and itching • May be less effective in improving symptoms • The dose can be taken at home • They do not have much risk of anaphylactic shock • They do not have hefty procedures

Table 1: Comparison between subcutaneous and sublingual immunotherapy [29,30,31]

SLIT is a type of immunotherapy with no serious risk evidence and follows a great safety profile based on clinical trials performed for 20 years. Also, the SLIT was proved to be safe in children below 5years, where during the clinical trials the only notable side effects were local itching and oral discomfort. Only in few cases diarrhea and or abdominal pain was observed.

There were certain needs which were not met in SLIT as there is hassle between manufacturers for attaining uniformity of standardized vaccines and the extent of their clinical efficacy and also a crucial query regarding the early intervention with SLIT in small children having IgE mediated disorder was seen. There is a future scope for this route of SLIT in enhancing the treatment of patients having IgE-mediated disorders.[32]

- One of the major challenges faced during subcutaneous immunotherapy was due to its safety and another factor was the inconvenience based on duration and also the need to visit the clinics for injections.
- Sublingual immunotherapy too faces a sort of challenge based on the duration and also the certain liquid extracts having undefined doses.
- The existing unstandardized extracts in both subcutaneous and sublingual immunotherapy require standardization, quality enhancement, and dosage determination.

- Another significant challenge in allergen immunotherapy is determining the effectiveness of the multiallergen mixture. To demonstrate dose and efficacy, less expensive alternatives to randomized, double-blind, placebo-controlled studies are being developed.[33]

Benefits of SCIT over SLIT

- Most allergy sufferers are allergic to many allergens. Shots can offer relief for more than one allergy, however SLIT treatments can only offer relief for one allergy.
- Additionally, allergy injections have been shown to be useful in the treatment of allergies to ragweed relatives such as avocado, melon, and other fruits. It's uncertain if the new ragweed allergy pills will provide this protection.

Indications of allergen immunotherapy

- Insufficient manifestation control regardless of pharmacotherapy and evasion gauges, a longing to diminish dreariness from unfavorably susceptible rhinitis or potentially asthma, or lessen the danger of hypersensitivity from a future bug sting, when the patient encounters unfortunate pharmacotherapy results, and when aversion is unimaginable are altogether signs for allergen immunotherapy. (34)

Conclusion

Immunotherapy includes giving the patient progressively higher doses of the medication or allergen to which the person is hypersensitive. At whatever point conceivable, normalized immunizations with set up strength ought to be used. Unfavorably susceptible asthma is an extreme constant ailment brought about by allergens that produce a response, which brings about the creation of immunomodulators and irritation, which confines the aviation routes causing asthma symptoms.

Allergen immunotherapy, both subcutaneous and sublingual, can shift the direction of the sickness. Subcutaneous is desirable over sublingual, it is insufficient at low portions and can have an unfortunate fundamental response at high dosages. Subcutaneous have a rapid response with the immune system as the medication is directly released into the blood.

As per our discoveries, the clinical examination brought about diminished lung tissue irritation, the quantity of eosinophils in bronchoalveolar liquid, allergen-explicit IgE (Immunoglobulin E), and IL-4(Interleukin-4) age when managing subcutaneous isopathic immunotherapy.

The creation of TGF- β (Changing Development Factor- β) and a particular administrative populace of Lymphocytes that ensures against allergens have additionally developed irrelevantly. Hence this review mainly figures out the novel method to treat allergic asthma by desensitization of a particular allergen that differ from a person to person and also focused the challenges faced by the use of sublingual and subcutaneous immunotherapy for allergic asthma.

References

1. Hafsa P V and Dr. Vidya Viswanad, "Pulmonary drug delivery-Determining attributes", International Journal of Research in Pharmaceutical Sciences, vol. 11, no. 3, pp. 3819 - 3827, 2020.DOI: <https://doi.org/10.26452/ijrps.v11i3.2556>
2. Quirt, J., Hildebrand, K. J., Mazza, J., Noya, F., & Kim, H. (2018). Asthma. Allergy, asthma, and clinical immunology: official journal of the Canadian Society of Allergy and Clinical Immunology, 14(Suppl 2), 50. <https://doi.org/10.1186/s13223-018-0279-0>

3. Surrena, H. (Ed.). (2010). Textbook of Medical-Surgical nursing (12th ed.) [E-book]. Wolters Kluwer Health / Lippincott Williams & Wilkins. https://zu.edu.jo/uploadfile/library/e_books/files/libraryfile_9134_13.pdf
4. Saritha C K, Josni Jose, Vidya Viswanad. Allergen Immunotherapy: Tactic in manipulating food allergen induced anaphylaxis. *Int. J. Res. Pharm. Sci.* 2020; 11(2):2533-2542. DOI: <https://doi.org/10.26452/ijrps.v11i2.2250>
5. Holgate S. T. (1999). The epidemic of allergy and asthma. *Nature*, 402(6760 Suppl), B2–B4. <https://doi.org/10.1038/35037000>
6. Fukuda T, Pathophysiology of Asthma, *Int Arch Allergy Immunol* 2000;121(suppl 1):25–31(DOI:10.1159/000053614)
7. Arya, VS, Kanthlal, SK, Geevarghese, L. The role of dietary polyphenols in inflammatory bowel disease: A possible clue on the molecular mechanisms involved in the prevention of immune and inflammatory reaction. *J Food Biochem.* 2020; 44:e13369. <https://doi.org/10.1111/jfbc.13369>
8. C.D.S.M.D. (2019, August 11). An overview of allergic asthma. WebMD. <https://www.webmd.com/asthma/guide/allergic-asthma#:~:text=Allergic%20asthma%20is%20the%20most,%2C%20dust%20mites%2C%20or%20mold>
9. Bousquet, J., Lockey, R., &Malling, H. J. (1998). Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. *The Journal of allergy and clinical immunology*, 102(4 Pt 1), 558–562. [https://doi.org/10.1016/s0091-6749\(98\)70271-4](https://doi.org/10.1016/s0091-6749(98)70271-4)
10. N. Nair et al. Amidase, a cell wall hydrolase, elicits protective immunity against *Staphylococcus aureus* and *S. epidermidis*. *Int. J. Biol. Macromol.* 2015; 77:314–321.
11. Liu, J. L., Ning, W. X., Li, S. X., Xu, Y. C., Wu, L., Wang, Y. S., Xu, X. F., Jiang, Y., Sheng, Y. J., Zhou, Y. L., Wang, J. H., Tang, L. F., & Chen, Z. M. (2017). The safety profile of subcutaneous allergen immunotherapy in children with asthma in Hangzhou, East China. *Allergologia et Immunopathologia*, 45(6), 541–548. <https://doi.org/10.1016/j.aller.2017.04.002>
12. Eman O. Arram, Aida M. Yousef, Amal Fathy, Amany Atwa, Clinical and immunological effect of subcutaneous immunotherapy in allergic asthma, *Egyptian Journal of Chest Diseases and Tuberculosis*, Volume 66, Issue 2,2017, ISSN 0422-7638. <https://doi.org/10.1016/j.ejcdt.2016.10.004>.
13. Asamoah, F., Kakourou, A., Dhami, S., Lau, S., Agache, I., Muraro, A., Roberts, G., Akdis, C., Bonini, M., Cavkaytar, O., Flood, B., Izuhara, K., Jutel, M., Kalayci, Ö., Pfaar, O., & Sheikh, A. (2017). Allergen immunotherapy for allergic asthma: a systematic overview of systematic reviews. *Clinical and translational allergy*, 7, 25. <https://doi.org/10.1186/s13601-017-0160-0>
14. Tsabouri, S., Mavroudi, A., Feketea, G., &Guibas, G. V. (2017). Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children. *Frontiers in pediatrics*, 5, 82. <https://doi.org/10.3389/fped.2017.00082>
15. Shahram Shahabi, Ebrahim Mazloomi, Behrooz Ilkhanizadeh, Ahad Zare, (2020) Subcutaneous Isopathic Immunotherapy of Allergic Asthma in a Mouse Model of Allergic Asthma, *Homeopathy* 2020; 109(01): A1-A28, DOI: 10.1055/s-0040-1702082
16. Lin SY, Azar A, Suarez-Cuervo C, Diette GB, Brigham E, Rice J, Ramanathan M, Gayleard J, Robinson KA. The Role of Immunotherapy in the Treatment of Asthma. Comparative Effectiveness Review No. 196 (Prepared by the Johns Hopkins University

- Evidence-based Practice Center under AHRQ Publication No. 17(18)-EHC029-EF. Rockville, MD: Agency for Healthcare Research and Quality. March 2018. Posted final reports are located on the Effective Health Care Program search page. DOI: <https://doi.org/10.23970/AHRQEPCCER196>
17. Dantzer, J. A., & Wood, R. A. (2018). The use of omalizumab in allergen immunotherapy. *Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology*, 48(3), 232–240. <https://doi.org/10.1111/cea.13084>
18. J. Coutinho Costaa, J.N. Machadoa, C. Ferreira, J.M.R. Gamab, T. Almeidaa, A.M. Arrobasa, (2019), Immunotherapy in Allergic Asthma – 5-year analysis: Is it a curative approach, *Pulmonology*, Volume 25, Issue 3, Pages 183-185, ISSN 2531-0437, <https://doi.org/10.1016/j.pulmoe.2019.01.007>
19. Stephen R. Durham, MA MD FRCP, G. W. C. M. D. (2011, August 11). Allergen Immunotherapy for allergic rhinitis and asthma: A Synopsis. WORLD ALLERGY ORGANIZATION; a World Federation of Allergy, Asthma and Clinical Immunology Societies. <https://www.worldallergy.org/education-and-programs/education/allergic-disease-resource-center/professionals/allergen-immunotherapy-a-synopsis>
20. Sublingual immunotherapy (SLIT). (n.d.). American College of Allergy, Asthma & Immunology. Retrieved June 2, 2021, from <https://acaai.org/allergies/allergy-treatment/allergy-immunotherapy/sublingual-immunotherapy-slit>
21. S Creticos, MD, P. S. C. (2021, May 1). Sublingual immunotherapy for allergic rhinoconjunctivitis and asthma. Uptodate. <https://www.uptodate.com/contents/sublingual-immunotherapy-for-allergic-rhinoconjunctivitis-and-asthma>
22. ALLERGY SHOTS AND WAITING PERIOD. (2016, April 7). Bluegrass Family Allergy Website Development by M&R Marketing Group. <https://www.bluegrassfamilyallergy.com/allergy-injections-and-waiting-period/>
23. Fortescue, R., Kew, K. M., & Leung, M. (2020). Sublingual immunotherapy for asthma. *The Cochrane database of systematic reviews*, 9(9), CD011293. <https://doi.org/10.1002/14651858.CD011293.pub3>
24. Canonica, MD, R. Durham, MA MD FRCP, G. W. S. (2016, August 11). Allergen immunotherapy for allergic rhinitis and asthma: A synopsis. World Allergy Organization, a World Federation for Allergy, Asthma and Clinical Immunology Societies. <https://www.worldallergy.org/education-and-programs/education/allergic-disease-resource-center/professionals/allergen-immunotherapy-a-synopsis>
25. Asamoah, F., Kakourou, A., Dhami, S., Lau, S., Agache, I., Muraro, A., Roberts, G., Akdis, C., Bonini, M., Cavkaytar, O., Flood, B., Izuhara, K., Jutel, M., Kalayci, Ö., Pfaar, O., & Sheikh, A. (2017). Allergen immunotherapy for allergic asthma: a systematic overview of systematic reviews. *Clinical and translational allergy*, 7, 25. <https://doi.org/10.1186/s13601-017-0160-0>
26. Fortescue R, Kew KM, Leung Mshiu Tsun. (2021) Sublingual immunotherapy for asthma. *Cochrane Database of Systematic Reviews* 2020, Issue 9. Art. No.: CD011293. DOI: 10.1002/14651858
27. Fortescue, R., Kew, K. M., & Leung, M. (2020). Sublingual immunotherapy for asthma. *The Cochrane database of systematic reviews*, 9(9), CD011293. <https://doi.org/10.1002/14651858.CD011293.pub3>
28. Nelson H. S. (2018). Current and future challenges of subcutaneous and sublingual allergy immunotherapy for allergists in the United States. *Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology*

- Immunology, 121(3), 278–280. <https://doi.org/10.1016/j.anai.2017.12.013>
29. Lin SY, Azar A, Suarez-Cuervo C, Diette GB, Brigham E, Rice J, Ramanathan M, Gayleard J, Robinson KA. The Role of Immunotherapy in the Treatment of Asthma. Comparative Effectiveness Review No. 196 (Prepared by the Johns Hopkins University Evidence-based Practice Center under AHRQ Publication No. 17(18)-EHC029-EF. Rockville, MD: Agency for Healthcare Research and Quality. March 2018. Posted final reports are located on the Effective Health Care Program search page. DOI: <https://doi.org/10.23970/AHRQEPCCER196>
30. Jo, Hyung-Rae, & Hwangbo, Min. (2016), Sublingual immunotherapy for allergic rhinitis, The Journal of Korean Medicine Ophthalmology and Otolaryngology and Dermatology. 29(1), 131–144, 2016;29(1):131. <https://doi.org/10.6114/jkood.2016.29.1.131>
31. N Schellack, D Engler, (2016), Sublingual immunotherapy for the treatment of allergies, South African Family Practice 2016; 58(2):49-52
32. Pajno G. B. (2007). Sublingual immunotherapy: the optimism and the issues. The Journal of allergy and clinical immunology,119(4),796–801. <https://doi.org/10.1016/j.jaci.2007.01.009>
33. Nelson, Harold S, (2018), Current and future challenges of subcutaneous and sublingual allergy immunotherapy for allergists in the United States, Annals of Allergy, Asthma & Immunology, volume 121, issue 3, P278-280, DOI: <https://doi.org/10.1016/j.anai.2017.12.013>.
34. American collage of allergy, asthma and immunology. (n.d.). allergy immunotherapy. Retrieved June 2, 2021, <https://acaai.org/allergies/allergy-treatment/allergy-immunotherapy>
35. Georgy, Mary S.; Saltoun, Carol A., (2012), Allergy and Asthma Proceedings, Volume 33, pp. S9-S11(3), OceanSide Publications Inc DOI: <https://doi.org/10.2500/aap.2012.33.3533>